ASRS A project from the American Society of Retina Specialists
  1. Collections
  2. Updates from the Field

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

  • Diana V Do, MD, FASRS
  • Video
  • Published 2024

Related

Category: Retinal Vascular Disease

See more